| --- | --- | --- | |-----------------------------------------|--------------------------|----------------| | 雍禾医疗（ 增持（维持） | 2279.HK | ）：业绩承压延 | | 所属行业：医疗保健业 / 医疗保健设备和服 | | | | 务 当前价格 ( 港币 ) ： 1.15 元 | 续，关注龙头品牌长期价值 | | 投资要点 证券分析师 -86% -69% -51% -34% -17% 0% 17% 雍禾医疗 恒生指数 | --- | --- | --- | --- | --- | |-------------------------------------|-----------------|-------|-----------------|---------------| | -103% 2023-03 \n恒 生 指 数 对 比 | 2023-07 \n1M | | 2023-11 \n2M | 3M | | 绝对涨幅 (%) 相对涨幅 (%) | -46.70 -44.33 | | ...

Yonghe Medical Group Co., Ltd. 雍禾醫療集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2279） 1 本公司權益持有人應佔每股虧損 每股基本虧損（人民幣元） 8 (1.08) (0.16) 每股攤薄虧損（人民幣元） 8 (1.08) (0.16) 2 合併財務報表附註 雍禾醫療集團有限公司（「本公司」）於2020年9月17日根據開曼群島法例第22章《公司法》 （1961年第3號法例，經綜合及修訂）於開曼群島註冊成立為獲豁免有限公司。本公司的註 冊辦事處地址為Floor 4, Willow House, Cricket Square, Grand Cayman KY 1-9010, Cayman Islands。 除另有說明外，此等合併財務報表以人民幣（「人民幣」）呈列，且所有金額乃四捨五入至 最接近的人民幣千元（「人民幣千元」）。 2 編製基準 香港財務報告準則包括以下權威文獻 • 香港會計準則 (iii) 本集團採用的新訂及經修訂準則 • 與單一交易產生的資產及負債有關的遞延稅項－香港會計準則第12號之修訂 5 1,777,258 1,412,791 經營分部按與 ...

管理層討論與分析 MANAGEMENT DISCUSSION AND ANALYSIS 業務進展 持續強化運營能力 領先的運營能力，讓我們能有效控制成本、 提高運營效率和盈利能力。我們的商業模式 具有高度可拓展性，不僅能使我們實現在地 理上的快速拓展，亦能促進我們在服務項目 和服務細分方式上實現高效拓展。報告期 內，我們重點在二三線城市進行雍禾植髮門 店的下沉拓展，同時繼續在廣深地區擴大史 雲遜醫學健髮中心獨立店佈局的規模。我 們新建i）9家雍禾植髮院部，主要分佈於廣 東、河南、湖北、山東的二三線城市，並新 增對中國西北地區如寧夏和青海的覆蓋；及 ii）5家史雲遜院部，分佈於深圳及廣州。 下表載列所示期間植髮醫療機構按發展階段* 劃分的數量明細： BUSINESS UPDATES Continuously strengthening operational capabilities Our leading operational capability enables us to effectively control our costs and enhance our operational efficien ...

截至2023年6月30日止六個月 中期業績公告 | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------|-----------|------------------------------------------------------------|----------------------------------------------| | | 附註 | 截至 6 月 30 2023 年 人民幣千元 未經審核 | 日止六個月 2022 年 人民幣千元 未經審核 | | 來自客戶合約的收入 銷售及服務成本 | 4 6 | 827,807 (360,209) | 748,137 (267,641) | | 毛利 | | 467,598 | 480,496 | | | 6 | | | | 銷售及營銷開支 一般及行政開支 研發開支 金融資產（減值虧損）╱撥回收益淨額 其他收入 其他虧損－淨額 | 6 ...

Shareholding Structure - The company's total number of shares issued as of December 31, 2022, was 527,080,416[9] - ZY Investment Capital Ltd holds 161,531,916 shares, representing 30.65% of the issued share capital[14] - Yonghe Hair Service Holdings Limited holds 91,866,668 shares, representing 17.43% of the issued share capital[14] - Panmao (Shanghai) Investment Centre (Limited Partnership) holds 183,733,336 shares, representing 34.86% of the issued share capital[14] - CITIC Private Equity Funds Management Co., Ltd. holds 183,733,336 shares, representing 34.86% of the issued share capital[14] - CYH Cosmetic Medical Holdings Limited holds 91,866,668 shares, representing 17.43% of the issued share capital[14] - CPEChina Fund II, L.P. holds 183,733,336 shares, representing 34.86% of the issued share capital[14] - CPEChina Fund IIA, L.P. holds 183,733,336 shares, representing 34.86% of the issued share capital[14] - Citron PE Associates II, L.P. holds 183,733,336 shares, representing 34.86% of the issued share capital[16] - CITIC Securities Company Limited holds 184,388,336 shares, representing 34.98% of the issued share capital[16] - Frandor Limited holds 655,000 short positions and 185,531,916 long positions, representing 0.12% and 35.20% of the issued share capital respectively[16] - Trident Trust Company (Singapore) Pte Limited holds 185,531,916 shares, representing 35.20% of the issued share capital[16] - The total number of issued shares as of December 31, 2022, is 527,080,416[17] - ZY Investment Capital Ltd is wholly owned by ZY Ventures Ltd, which is wholly owned by Frandor Limited[19] - Yonghe Hair Service Holdings Limited is wholly owned by Panmao Shanghai, which is wholly owned by CITIC Private Equity Funds Management Co., Ltd[22] - CYH Cosmetic Medical Holdings Limited is wholly owned by CYH Cosmetic Medical Investment Limited, which is owned 86.3% by CPEChina Fund II, L.P. and 13.7% by CPEChina Fund IIA, L.P.[23] Equity and Share Transactions - No equity-linked agreements were entered into by the company or its subsidiaries during the reporting period[4] - No shares were purchased, sold, or redeemed by the company or its subsidiaries during the year ended December 31, 2022[5] - The company has not entered into any equity-linked agreements during the reporting period[25] Business Overview and Strategy - The company is a leading medical group in China specializing in hair medical services, offering a one-stop solution including hair transplantation, medical hair care, and other related services[32] - The Group has built a one-stop medical hair care service system to meet the medical needs of a wide range of patients, leveraging a standardized and highly scalable business model to achieve industry-leading operational capabilities[33][36] - The Group has expanded its footprint outside mainland China by acquiring the Hong Kong business of Nu/Hart Hair, a renowned hair transplant service provider from the U.S.[35] - The Group collaborates with experts from Class IIIA hospitals and renowned academic institutions to improve diagnostic, therapeutic, and R&D capabilities[33][36] - The Group actively promotes the adoption of new technologies, including data usage and analysis, intelligent services, and online services, to enhance medical services and business development[33][36] - The Group has established a Svenson Medical Hair Care Center in each of its clinics in mainland China under the "shop-in-shop" and "stand-alone shop" models[35] - The Group has made Yonghe Hair Transplant a well-known and highly trusted brand in China's hair-related healthcare industry[35] - The Group is enhancing its core competitiveness and strengthening its leading position in the industry through collaborative R&D with prestigious universities such as Sun Yat-sen University[35] - The company plans to expand the number of hair transplant medical clinics to nearly 85 by the end of 2023[50] - The company aims to enhance its nationwide medical service network by intensifying its presence in first-tier and new first-tier cities and expanding into sinking markets[51] - The company is expanding its medical hair care business, focusing on transforming hair transplant clinics into comprehensive hair hospitals in key cities[52] - The company is building a brand portfolio across the full industry chain, including "Yonghe Hair Transplant," "Svenson," "Fa Zhi Chu," and "Hafada"[52] - The company's strategy focuses on technological innovation, talent development, and improving customer service experience to adapt to market changes[63][64] - The company is transforming hair transplant clinics into comprehensive hair hospitals, with a new hospital in Shanghai already operational and one in Beijing expected to open by mid-2023[124][126] - The company is developing a digital marketing platform to improve customer acquisition and conversion efficiency, aiming to reduce marketing costs[128] - The company is enhancing its digital service platform with internet hospitals to improve online service capabilities and optimize surgery quality control systems[128] - The company is building a digital collaborative operation platform to integrate supply chain, finance, medical services, and manpower processes, aiming to improve data insight efficiency[129][133] - The company is expanding its Svenson medical hair care centers, focusing on product diversification and increasing geographic presence to enhance brand awareness and market share[118][121] Financial Performance - Revenue from contracts with customers in 2022 was RMB 1,412.8 million, a decrease from RMB 2,168.6 million in 2021[47] - Gross profit for 2022 was RMB 872.6 million, down from RMB 1,580.0 million in 2021[47] - Net loss for 2022 was RMB 85.9 million, compared to a net profit of RMB 120.2 million in 2021[47] - Gross profit margin decreased to 61.8% in 2022 from 72.9% in 2021[47] - Total assets at the end of 2022 were RMB 2,930.4 million, down from RMB 3,199.3 million in 2021[47] - Cash and cash equivalents decreased to RMB 565.1 million in 2022 from RMB 1,566.2 million in 2021[47] - Revenue for the year ended December 31, 2022, was RMB1,412.8 million, with a gross profit of RMB872.6 million and a gross profit margin of 61.8%[73][78] - Hair transplant service revenue accounted for 72.9% of total revenue, amounting to RMB1,030.5 million, with a gross profit margin of 62.4%[79][80] - Medical hair care service revenue was RMB362.5 million, representing 25.7% of total revenue, with a gross profit margin of 61.8%[79] - Revenue from hair transplant service reached RMB1,030.5 million, accounting for 72.9% of total revenue in 2022[81] - Number of patients who underwent hair transplant surgery in 2022 was 39,254, a decrease from 58,464 in 2021[83] - Average spending per hair transplant patient was RMB26,251 in 2022, slightly down from RMB26,643 in 2021[83] - Revenue from medical hair care service amounted to RMB362.5 million, representing 25.7% of total revenue in 2022[87] - Number of patients who received medical hair care service in 2022 was 63,257, with a repurchase rate of 28.2%[87][90] - Average spending per medical hair care patient increased to RMB5,731 in 2022 from RMB5,531 in 2021[90] - In 2022, the company's total revenue was RMB1,412.8 million, a decrease of 34.9% compared to 2021, primarily due to a decline in hair transplant service revenue[134] - Hair transplant service revenue in 2022 was RMB1,030.5 million, a 34.2% decrease from 2021, driven by a 40.0% drop in customer visits and 39,254 hair transplant patients[136] - The company's medical hair care service revenue in 2022 was RMB362.5 million, accounting for 25.7% of total revenue, a decrease from 26.8% in 2021[135] - Revenue from hair transplant service decreased by 34.2% to RMB1,030.5 million in 2022, with the number of patients dropping to 39,254 due to a 40.0% decline in store customer flow[137] - Revenue from medical hair care service decreased by 37.7% to RMB362.5 million in 2022, with the number of patients served at 63,257 and average spending per patient increasing to RMB5,731[140][142] - Other income from independent Svenson stores decreased slightly to RMB19.8 million in 2022[141][143] - Total costs decreased by 8.2% to RMB540.2 million in 2022, with staff costs accounting for 38.6% and amortization and depreciation charges increasing to 36.0%[145][146] - Gross profit decreased by 44.8% to RMB872.6 million in 2022, with gross profit margin dropping to 61.8% due to pandemic impacts and higher fixed costs[147][149] - Other income, including government grants and VAT credits, increased to RMB9.7 million in 2022[148][150] - General and administrative expenses increased to RMB257.5 million in 2022, with staff costs making up 65.4% of the total[151][154] - Selling and marketing expenses decreased to RMB766.8 million in 2022, primarily driven by reduced marketing and promotion expenses[156] - Marketing and promotion expenses decreased to RMB492.3 million in 2022 from RMB684.3 million in 2021, a reduction of 28.1%[157] - Net loss of RMB85.9 million in 2022, compared to a net profit of RMB120.2 million in 2021, representing a 171.4% decrease[158][161] - Cash and cash equivalents decreased to RMB565.1 million in 2022 from RMB1,566.2 million in 2021[162][163] - Net cash used in operating activities was RMB108.6 million in 2022, compared to net cash generated of RMB437.3 million in 2021[166] - Net cash used in investing activities increased to RMB650.6 million in 2022 from RMB193.9 million in 2021[166] - Cash and cash equivalents and term deposits totaled RMB978.0 million in 2022, including RMB412.9 million in term deposits[168][178] - The Group had no bank borrowings as of December 31, 2022, compared to RMB74.2 million in 2021[162][163] - Staff costs decreased to RMB225.9 million in 2022 from RMB318.9 million in 2021, a reduction of 29.2%[157] - Income tax credit of RMB23.6 million in 2022, compared to an income tax expense of RMB90.1 million in 2021[160] - The Group's net profit margin dropped from 5.5% in 2021 to -6.1% in 2022[158][161] - Capital expenditures increased to RMB243.5 million in 2022, up from RMB190.6 million in 2021, driven by business expansion[183] - Inventories rose to RMB88.1 million in 2022, compared to RMB53.1 million in 2021[183] - Trade and other payables decreased to RMB144.1 million in 2022 from RMB225.7 million in 2021, primarily due to full settlement of Nu/Hart Hair acquisition payments and reduced accrued expenses[183] - Total indebtedness stood at RMB1,035.6 million in 2022, slightly down from RMB1,046.9 million in 2021, with no outstanding bank borrowings as of December 31, 2022[186] - Lease liabilities increased to RMB1,035.6 million in 2022 from RMB947.4 million in 2021, reflecting ongoing lease commitments[186] - The Group's gearing ratio was nil in 2022, compared to 4.4% in 2021, due to the absence of bank borrowings[189] - Cash and cash equivalents denominated in foreign currencies decreased to RMB272.6 million in 2022 from RMB1,180.7 million in 2021, primarily in USD and HKD[189] - The Group had no material contingent liabilities, significant investments, or asset charges as of December 31, 2022[189] - No significant foreign currency risk was reported, as all operations, assets, and liabilities are denominated in RMB[189] - The Group did not make any material acquisitions or disposals of subsidiaries, associates, or joint ventures during 2022[189] - The company had a total of 3,741 employees as of December 31, 2022, with 1,341 being part of the professional medical team[190] - Staff costs for the year ended December 31, 2022, were RMB616.7 million, a decrease from RMB700.3 million in the previous year[190] - The company adopted a restricted share units scheme on July 26, 2022, to incentivize employees and attract talent, but no units were granted by December 31, 2022[190] - The Board resolved not to declare any final dividend for the year ended December 31, 2022[190] Operational Metrics and Expansion - The company operated 60 Yonghe Hair Transplant clinics, 3 Yonghe Fa Zhi Chu female hair transplant clinics, and 9 independent Svenson shops in 60 cities across China as of December 31, 2022[49] - The repurchase rate of the medical care business remained high at 28.2%, with an average price per customer transaction of RMB 5,731 in 2022[49] - The company operated 63 hair transplant clinics and 9 stand-alone Svenson stores across 60 cities in China as of December 31, 2022[67][75] - The number of hair transplant clinics increased from 54 in 2021 to 63 in 2022, with significant growth in tier-two and tier-three cities[71] - Stand-alone Svenson stores increased from 3 in 2021 to 9 in 2022, with new locations in Shenzhen and Guangzhou[71] - The company served 39,254 hair transplant patients in 2022[80] - The company's brand matrix includes Yonghe Hair Transplant, Svenson, Fa Zhi Chu, and Harvard, covering the full industry chain of hair-related healthcare services[67][68] - The company introduced a doctor-centric pricing system in February 2022 to enhance brand trust and patient satisfaction[80] - Company expanded its presence by opening six Yonghe Hair Transplant clinics, three Fa Zhi Chu Female Hair Transplant clinics, and six Svenson centers in 2022[93] - Total number of hair transplant clinics reached 63, covering 60 cities across 28 provinces, autonomous regions, municipalities, and special administrative regions in China as of December 31, 2022[93] - Mature-stage clinics increased to 37 in 2022 from 30 in 2021, while newly-established clinics rose to 9 from 6[95] - The company treated a total of 104,380 patients in 2022, with expectations of continued growth in demand for hair loss treatment and care[116] - The Chinese hair medical services market is projected to grow from RMB 18.4 billion in 2020 to RMB 138.1 billion in 2030, with a CAGR of 22.3%[116] - The hair-related healthcare service market in China is projected to grow from RMB18.4 billion in 2020 to RMB138.1 billion in 2030, with a CAGR of 22.3%[119] Medical Team and Physician Development - The company has a professional medical team of 1,341 members, including 294 doctors as of December 31, 2022[55] - The company launched a hierarchical diagnosis and treatment system for hair transplant physicians in February 2022[55] - The company completed the integration reform of reception and diagnosis across all medical institutions in Mainland China by June 2022[55] - The company introduced the "Physician Improvement Program" in September 2022 to enhance doctors' professionalism and service efficiency[55] - The company launched a physician value-based hierarchical diagnosis and treatment system for hair transplant physicians in February 2022, focusing on academic skills, surgical experience, and customized design standards[99] - By June 2022, all clinics in Mainland China implemented the physician consultation system, leading the industry in consultation integration reform[99] - In September 2022, the company upgraded its "Good Physician System" to the "Strong Physician Program," emphasizing technology realization, disease diagnosis, and physician value[100][105] - As of December 31, 2022, the company had 1,341 medical professionals, including 294 physicians, and established a "Hair Transplant Physician Grading and Evaluation System" with 4 appraisal indicators and 24 assessment dimensions[100][105][106] - The company developed and launched an integrated consultation management system to enhance physician consultation efficiency and digital diagnostic capabilities[104] - The company upgraded operational informatization, including appointment scheduling, intelligent hair loss area measurement, and integrated treatment processes, improving patient experience[104] - The company's medical team consists of 1,341 professionals, including 294 physicians, 959 nurses, and 88 other medical professionals (pharmacists and clinical scientists)[106] - The company developed an integrated consultation management system to improve physician efficiency and enhance digital diagnosis and treatment services[109] - The company upgraded its business operation system with IT enhancements, including smart photogrammetry for hair loss area measurement and operational data dashboards[109] Research and Development - The company is investing in cutting-edge research on stem cell technology and hair follicle cloning to explore new hair therapy solutions[56] - The company is leveraging big data, cloud computing, and AI technologies to improve diagnosis and treatment efficiency[56] - The company is developing a digital online medical platform to enhance patient-doctor communication and improve patient experience[56] - The company is optimizing hair transplantation equipment to improve surgical experiences for patients[56] - The company

醫療養固業務 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 (I)截至2022年12月31日止年度的年度業績公告 及(II)所得款項用途改變 1 合併全面收益表 | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------|-------|--------------------------------------------------------------------|----------------------------------------------------------| | | 附註 | 截至 12 月 31 2022 年 人民幣千元 | 日止年度 2021 年 人民幣千元 | | 來自客 ...

雍禾醫療集團有限公司 YONGHE MEDICAL GROUP CO., LTD. YONGHE MEDICAL GROUP CO., LTD. 雍禾醫療集團有限公司 （於開曼群島註冊成立的有限公司） （incorporated in the Cayman Islands with limited liability） 股份代號 Stock Code : 2279 2022 Interim Report 中期報告 r 頁次 Page 公司簡介 2 Company Profile 公司資料 3 Corporate Information 財務概要 6 Financial Summary 管理層討論與分析 7 Management Discussion and Analysis 企業管治及其他資料 27 Corporate Governance and Other Information 中期財務資料的審閱報告 41 Report On Review of Interim Financial Information 中期簡明合併全面收益表 42 Interim Condensed Consolidated Sta ...

YONGHE MEDICAL GROUP CO., LTD. 雍禾醫療集團有限公司 （於開曼群島註冊成立的有限公司） （incorporated in the Cayman Islands with limited liability） 股份代號 Stock Code : 2279 09 18度 Annual Report 2021 年報 目 錄 | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|--------------------------------------------------------------------|----------| | | | | | | CONTENTS | | | | | | 公司簡介 | 2 | | | | | | Company Profile 公司資料 | 3 | | | | | | Corporate Information 財務概要 | 6 | | | | | | Financial Summary 主席報告 | 7 | | | | | | Chairman's S ...